SPRO Spero Therapeutics, Inc. Common Stock
XNAS
1.07
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
SPRO
$1.07
—
What changed
Recent filings, trades and movesKey stats
$1.07
- 52-Week Range
- $0.96 – $3.08
- YTD
- -54.26%
- Straddle Price
- $0.50
- P/C Vol Ratio
- 10.89
- Market Cap
- $0.1B
- Open
- $1.03
- Day Range
- $1.00 – $1.08
- Volume
- 353,575
- Prev Close
- $1.03
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.09 |
| Cost of Equity (CAPM) | 10.88% (VRP-adj) |
| WACC | 10.94% |
| Volatility Risk Premium | +226.3pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 1.7% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 12 years explicit + fade |
| Free Cash Flow (TTM) | $0.0B |
| Return on Equity (TTM) | 16.7% |
| Book / Price | 89.7% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | 32.0% |
| Debt / Equity | 0.00 |
| Quality Score | 4/6 — high quality (12y DCF) |
| SMA 50 | $1.16 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $1.11 |
| Bollinger Width / SMA20 | 19.4% (drives anchor stability) |
| Net Debt | $-0.1B |
| Market Cap | $0B |
Peers used for multiples: INGN, KIDS, MYGN, PCRX
(filtered from 8 ETF-co-members; sector bias active)
60-Day Conviction
82%
20-Day Fair Value
≈ by Dec 8, 2026
$1.07
α -0.1%
rank 92%
conviction
6%
40-Day Fair Value
≈ by Jan 6, 2027
$1.10
α +2.0%
rank 90%
conviction
63%
60-Day Fair Value
≈ by Feb 4, 2027
$1.12
α +4.1%
rank 93%
conviction
82%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $2.97 | 26% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | |
| Peer P/B | $1.91 | 5% | median 2.1× · 4 peers |
| Peer P/S | $1.44 | 15% | median 1.4× · 4 peers |
| Market Anchor (SMA50) | $1.16 | 54% | stability 53% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.1B
- Employees
- 25
- List Date
- 2017-11-02
- CIK
- 0001701108
- Next Earnings
- 2026-11-12 (Pre-Market)
- EPS Forecast
- ($0.47)
- Headquarters
- Cambridge, MA
- Homepage
- https://www.sperotherapeutics.com
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is al…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 1.00% | -21.65% | 6.32% | 0.00% | -20.69% | -6.81% | -6.97% |
| Feb | -5.27% | -14.13% | -21.28% | 5.10% | -3.40% | -2.69% | -6.95% |
| Mar | -21.74% | -8.32% | -3.97% | 1.78% | -6.51% | 6.85% | -5.32% |
| Apr | -3.64% | -31.65% | 16.45% | -20.67% | -5.19% | 2.45% | -7.04% |
| May | 4.62% | -76.82% | -5.95% | -8.09% | 278.79% | 14.11% | 34.44% |
| Jun | -4.90% | -30.75% | -19.44% | -9.09% | 5.84% | -21.91% | -13.38% |
| Jul | -18.61% | -11.51% | 10.88% | 10.16% | -20.00% | -47.30% | -12.73% |
| Aug | 39.29% | 17.78% | -1.32% | -1.44% | -10.00% | 6.09% | 8.40% |
| Sep | 5.32% | 162.33% | -20.39% | 0.00% | -8.29% | 0.83% | 23.30% |
| Oct | 0.06% | -2.97% | -9.24% | -6.11% | 23.98% | -15.87% | -1.69% |
| Nov | -18.71% | -1.52% | 0.00% | -3.39% | 0.84% | 3.85%* | -3.15% |
| Dec | 11.10% | -9.42% | 25.64% | -8.85% | 2.64% | -- | 4.22% |
| Total | -22.54% | -83.99% | -29.56% | -36.35% | 130.69% | -56.43% | -16.36% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.10
SMA 50: $1.15
SMA 200: $1.94
Current: $1.07
EMA 12: $1.08
EMA 26: $1.11
MACD: -0.0364 | Signal: -0.0044
BEARISH
ADX (14): 15.96
RANGE
+DI: 20.88
−DI: 24.82
Momentum Oscillators
RSI (14): 45.18
NEUTRAL
Stoch %K: 29.32
Stoch %D: 21.98
Williams %R: -57.92
Volume & Volatility
BB Upper: $1.21
BB Lower: $1.00
NEUTRAL
OBV: 197,966,410
Vol SMA 20: 360,631
Vol ROC: -31.62%
ATR: $0.07
True Range: $0.08
HV 20: 61.5%
HV 30: 58.1%
HV 60: 59.9%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Written before SPRO’s Aug 12 earnings report, so it doesn’t reflect the results.
Here is a comprehensive stock analysis report for SPRO:
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Technical indicators suggest a neutral trend, with a short-term downtrend and medium-term sideways movement
- Recent news sentiment is mixed, with positive headlines on the licensing agreement with GSK and negative news on potential delisting from Nasdaq
Primary Risks:
- Continued volatility and lack of clear direction in the stock price
- Potential for further decline if earnings miss expectations or regulatory issues arise
Investment Thesis: SPRO has the potential to rebound if it can stabilize its trend and improve its earnings outlook. However, it is essential to monitor the stock's technical indicators and news sentiment closely.
Recent News Sentiment Impact: The recent news headlines have had a mixed impact on the stock price, with positive news on the licensing agreement driving short-term gains, but negative news on potential delisting from Nasdaq weighing on the stock.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): Downtrend
- Medium-term (1-3 months): Sideways movement
- Long-term (3-12 months): Uptrend
Support/Resistance Levels:
- Upper resistance level: $2.44 (Bollinger Bands upper band)
- Middle support level: $2.29 (SMA 50)
- Lower support level: $2.14 (Bollinger Bands lower band)
Momentum Signals:
- RSI interpretation: Neutral (40.64), not oversold or overbought
- MACD signal: Bearish (-0.03 / Signal: -0.01 / Histogram: -0.02)
- Bollinger Bands position: Neutral, with the price touching the middle band
Volume Analysis:
- Volume SMA 20: 380137.70 (indicating moderate volume)
- On-Balance Volume (OBV): 218245610.00 (indicating increasing buying pressure)
- Volume Rate of Change: 60.88% (indicating increasing volume)
News & Sentiment Analysis
Recent Headlines Summary: The recent news headlines have been mixed, with positive news on the licensing agreement and negative news on potential delisting from Nasdaq.
Sentiment Assessment: Neutral sentiment, with a mix of positive and negative news driving the stock price.
Catalyst Identification: Earnings announcements, regulatory changes, and product launches could impact the stock price in the near term.
Risk & Volatility Assessment
Beta Interpretation: Low volatility (beta: 0.43), indicating that the stock moves less than the market.
Volatility Regime: Low volatility regime, with the stock experiencing moderate fluctuations.
Options Market Signals: Medium IV rank (73.7%), indicating historically average volatility. The options market is pricing a $0.88 move by expiration.
Downside Protection: Support levels at $2.29 and $2.14 could provide some downside protection if the stock experiences further declines.
Market Context & Positioning
Sector Performance: SPRO's sector (Healthcare) has been relatively strong, with the Nasdaq healthcare index up 12% over the past quarter.
Institutional Activity: Moderate institutional interest in the options market, with a put/call volume ratio of 1.19 indicating neutral sentiment.
Correlation Analysis: The stock is positively correlated with the market (R-squared: 0.03), indicating that it tends to move in line with broader market trends.
Key Levels & Action Items
Critical Price Levels: Support at $2.29 and $2.14, resistance at $2.44.
Breakout/Breakdown Levels: A breakout above $2.44 could signal a trend reversal, while a breakdown below $2.14 could indicate further declines.
Time-Sensitive Catalysts: Earnings announcements, regulatory changes, and product launches could impact the stock price in the near term.
Risk Management: Consider setting stop-loss levels at $2.15 to limit potential losses if the stock experiences further declines.
I hope this comprehensive analysis meets your requirements!
Generated
News
All SPRO news →
Earnings History
15 of 15 under expected move
Avg Expected Move
88.36%
Avg Actual Move
3.58%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-03-11 | Pre-Market | 49.37% | 6.86% | 0.14x | Within |
| 2021-08-05 | Pre-Market | 7.32% | 3.73% | 0.51x | Within |
| 2021-11-10 | Pre-Market | 23.75% | 1.39% | 0.06x | Within |
| 2022-03-31 | Pre-Market | 42.39% | 1.05% | 0.02x | Within |
| 2023-08-10 | Pre-Market | 29.66% | 0.00% | 0.00x | Within |
| 2024-01-05 | Pre-Market | 29.25% | 2.72% | 0.09x | Within |
| 2024-08-05 | Pre-Market | 163.16% | 2.29% | 0.01x | Within |
| 2024-10-29 | After-Close | 145.82% | 1.53% | 0.01x | Within |
| 2024-11-14 | Pre-Market | 116.41% | 4.58% | 0.04x | Within |
| 2025-03-27 | Pre-Market | 382.02% | 3.36% | 0.01x | Within |
| 2025-05-13 | After-Close | 177.54% | 5.78% | 0.03x | Within |
| 2025-08-12 | Pre-Market | 25.00% | 7.27% | 0.29x | Within |
| 2025-11-13 | Pre-Market | 28.20% | 8.27% | 0.29x | Within |
| 2026-03-26 | After-Close | 24.26% | 1.69% | 0.07x | Within |
| 2026-08-12 | Pre-Market | 81.30% | 3.25% | 0.04x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
SPRO Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $0.50
7-DTE Move: $0.57
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 97
Put Volume: 1,056
P/C Volume: 10.887
BEARISH
Call OI: 2,826
Put OI: 1,168
P/C OI: 0.413
Total OI: 3,994
ATM Options Pricing
ATM Call: $0.38
ATM Put: $0.12
Call %: 34.9%
Put %: 11.6%
Chain Summary
Chain Volume: 1,153
Chain OI: 3,994
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 10th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
10%
vs own history
GEX tilt
-0.04
OI-weighted, today
Vanna tilt
-0.09
δ-sensitivity to IV
Charm tilt
+0.03
δ-decay vs time
? What is this?
· 3 ATM contracts, 0k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$0.50Nov 9
Beta Analysis
Risk Metrics
Beta: 1.4855
Alpha: -80.11%
Correlation: 0.3188
R-Squared: 10.2%
Stock Volatility: 64.2%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own SPRO
3 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $2.1M | #1933 of 3138 | -20.3% | 13F | |
| Point72 Hedge fund Steve Cohen | $231K | #1761 of 1945 | +74.9% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $43K | #3689 of 3716 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
SPRO Institutional Ownership (13F)
Filings for 2026-06-30 · 17 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 57,157,101 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
4 filers$268.74K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC Custodian | $104.09K | 38.73% | 2026-06-30 |
| 2 | GROUP ONE TRADING LLC Custodian | $85.97K | 31.99% | 2026-06-30 |
| 3 | Simplex Trading, LLC Custodian | $48.40K | 18.01% | 2026-09-30 |
| 4 | Susquehanna International Group, LLP Custodian | $30.28K | 11.27% | 2026-06-30 |
5 filers$412.21K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Citadel Advisors LLC Custodian | $144.98K | 35.17% | 2026-06-30 |
| 2 | Simplex Trading, LLC Custodian | $82.04K | 19.90% | 2026-09-30 |
| 3 | Susquehanna International Group, LLP Custodian | $76.47K | 18.55% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $59.23K | 14.37% | 2026-06-30 |
| 5 | GROUP ONE TRADING LLC Custodian | $49.50K | 12.01% | 2026-06-30 |
SPRO Insider Trading (Form 4)
Latest: 2026-08-06Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | Debra Zack | Chief Medical Officer | Award (A) | +162,311 | — | EDGAR | |
| 2026-06-25 | Milind Deshpande | Director | Award (A) | +10,000 | — | EDGAR | |
| 2026-06-25 | Cynthia Smith | Director | Award (A) | +10,000 | — | EDGAR | |
| 2026-06-25 | Kathleen Tregoning | Director | Award (A) | +10,000 | — | EDGAR | |
| 2026-06-25 | John C Pottage Jr | Director | Award (A) | +10,000 | — | EDGAR | |
| 2026-06-25 | Frank E Thomas | Director | Award (A) | +10,000 | — | EDGAR | |
| 2026-06-25 | Scott Thomas Jackson | Director | Award (A) | +10,000 | — | EDGAR | |
| 2026-06-25 | Patrick V.J.J. Vink | Director | Award (A) | +10,000 | — | EDGAR | |
| 2026-05-06 | Esther Rajavelu | See Remarks | Sell (S) | −25,240 | $2.51 | -$63.4K | EDGAR |
| 2026-02-09 | Timothy Keutzer | Chief Operating Officer | Sell (S) | −18,652 | $2.36 | -$44.0K | EDGAR |
| 2026-02-09 | Esther Rajavelu | See Remarks | Sell (S) | −87,917 | $2.36 | -$207.5K | EDGAR |
| 2026-02-05 | Timothy Keutzer | Chief Operating Officer | Mixed Sell −46,586 · Grant +68,000 |
+21,414 | $2.17 | -$101.2K | EDGAR |
| 2026-02-04 | Esther Rajavelu | See Remarks | Mixed Grant +249,000 · Sell −18,442 |
+230,558 | $2.20 | -$40.6K | EDGAR |
| 2025-11-12 | Esther Rajavelu | See Remarks | Sell (S) | −40,270 | $2.37 | -$95.4K | EDGAR |
| 2025-09-03 | Ankit Mahadevia | Director | Sell (S) | −6,572 | $1.97 | -$12.9K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
SPRO Insider Holdings
12 insiders · @ $1.07
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Sath Shukla | CEO & President | 1,892,216 | $2.02M | -$305.7K | 11 | 2025-02-05 |
| 2 | Esther Rajavelu | See Remarks | 986,851 | $1.06M | -$476.0K | 9 | 2026-05-06 |
| 3 | Timothy Keutzer | Chief Operating Officer | 742,506 | $794.5K | -$246.4K | 12 | 2026-02-09 |
| 4 | Ankit Mahadevia | Director | 703,294 | $752.5K | -$1.04M | 24 | 2025-09-03 |
| 5 | Debra Zack | Chief Medical Officer | 162,311 | $173.7K | $0 | 1 | 2026-08-06 |
| 6 | Milind Deshpande | Director | 101,454 | $108.6K | $0 | 11 | 2026-06-25 |
| 7 | Frank E Thomas | Director | 85,000 | $91.0K | $0 | 12 | 2026-06-25 |
| 8 | John C Pottage Jr | Director | 85,000 | $91.0K | $0 | 9 | 2026-06-25 |
| 9 | Patrick V.J.J. Vink | Director | 85,000 | $91.0K | $0 | 13 | 2026-06-25 |
| 10 | Scott Thomas Jackson | Director | 85,000 | $91.0K | $0 | 8 | 2026-06-25 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
SPRO Board & Officers
As of SEC filings through Aug 6, 2026Directors 7
- Frank E Thomas · since Nov 1, 2017
- Milind Deshpande · since Nov 1, 2017
- Patrick V.J.J. Vink · since Nov 1, 2017
- John C Pottage Jr · since Sep 21, 2018
- Cynthia Smith · since Mar 19, 2019
- Scott Thomas Jackson · since Apr 16, 2020
- Kathleen Tregoning · since Oct 11, 2021
Officers 3
- Esther Rajavelu · Chief Executive Officer, Chief Financial Officer and Chief Business Officer · listed since May 2025
- Timothy Keutzer · Chief Operating Officer · listed since Feb 2024
- Debra Zack · Chief Medical Officer · since Aug 3, 2026
Changes in the last 10 years (46)
| Aug 3, 2026 | Debra Zack became Chief Medical Officer |
| Jan 30, 2026 | The company announced the departure of Ankit Mahadevia from the board in an SEC filing |
| May 6, 2025 | Esther Rajavelu listed as Chief Executive Officer, Chief Financial Officer and Chief Business Officer (previously CFO & Cbo) in SEC filings |
| Apr 22, 2025 | The company announced the departure of Sath Shukla from the board in an SEC filing |
| Nov 12, 2024 | Esther Rajavelu listed as CFO & Cbo (previously Chief Financial Officer and Chief Business Officer) in SEC filings |
| Feb 5, 2024 | Timothy Keutzer listed as Chief Operating Officer (previously Chief Development Officer) in SEC filings |
| Feb 5, 2024 | The company announced the departure of Tamara L Joseph as Chief Legal Officer in an SEC filing |
| Nov 6, 2023 | Esther Rajavelu became Chief Financial Officer and Chief Business Officer |
| Aug 3, 2023 | Sath Shukla listed as CEO and President (previously Chief Financial Officer) in SEC filings |
| Aug 3, 2023 | Sath Shukla first listed as a director in an SEC filing |
| Jun 14, 2023 | The company announced the departure of Ankit Mahadevia as CEO and President in an SEC filing |
| Sep 26, 2022 | Aquilo Capital, L.P. reported in an SEC filing no longer being a 10% owner |
| Sep 26, 2022 | Aquilo Capital Management, LLC reported in an SEC filing no longer being a 10% owner |
| Sep 12, 2022 | Kamal Hamed became Chief Medical Officer |
| Oct 11, 2021 | Kathleen Tregoning became a director |
| Jan 4, 2021 | Sath Shukla became Chief Financial Officer |
| Dec 2, 2020 | Tamara L Joseph became Chief Legal Officer |
| Sep 11, 2020 | Aquilo Capital, L.P. became a 10% owner |
| Sep 11, 2020 | Aquilo Capital Management, LLC became a 10% owner |
| Apr 16, 2020 | Scott Thomas Jackson became a director |
| Jan 1, 2020 | Timothy Keutzer became Chief Development Officer |
| Nov 8, 2019 | Stephen J. DiPalma became Interim CFO |
| Mar 19, 2019 | Cynthia Smith became a director |
| Sep 21, 2018 | John C Pottage Jr became a director |
| Feb 1, 2018 | David P Southwell became a director |
| Jan 4, 2018 | David A. Melnick became Chief Medical Officer |
| Nov 1, 2017 | Vikas Goyal became a director |
| Nov 1, 2017 | Thomas R Parr JR became Chief Scientific Officer |
| Nov 1, 2017 | Reza Halse became a director |
| Nov 1, 2017 | Patrick V.J.J. Vink became a director |
| Nov 1, 2017 | Milind Deshpande became a director |
| Nov 1, 2017 | Joel Sendek became Chief Financial Officer |
| Nov 1, 2017 | Jean Francois Formela became a director |
| Nov 1, 2017 | Invest A/S Lundbeckfond became a 10% owner |
| Nov 1, 2017 | Gv 2015, L.p. became a 10% owner |
| Nov 1, 2017 | Gv 2015 Gp, L.l.c. became a 10% owner |
| Nov 1, 2017 | Gsk Plc became a 10% owner |
| Nov 1, 2017 | Frank E Thomas became a director |
| Nov 1, 2017 | Cristina Larkin became Chief Operating Officer |
| Nov 1, 2017 | Casper Breum became a director |
| Nov 1, 2017 | Atlas Venture Fund IX, L.P. became a 10% owner |
| Nov 1, 2017 | Atlas Venture Associates IX, LLC became a 10% owner |
| Nov 1, 2017 | Atlas Venture Associates IX, L.P. became a 10% owner |
| Nov 1, 2017 | Ankit Mahadevia became a director |
| Nov 1, 2017 | Ankit Mahadevia became CEO and President |
| Nov 1, 2017 | Alphabet Inc. became a 10% owner |
Not reported recently (20)
- Sath Shukla · Last reported as CEO and President in an SEC filing dated Feb 5, 2025
- Kamal Hamed · Last reported as Chief Medical Officer in an SEC filing dated Feb 5, 2024
- Stephen J. DiPalma · Last reported as Interim CFO in an SEC filing dated Jul 24, 2023
- Gsk Plc · Last reported as a 10% owner in an SEC filing dated Nov 14, 2022
- Cristina Larkin · Last reported as Chief Operating Officer in an SEC filing dated Feb 3, 2022
- David A. Melnick · Last reported as Chief Medical Officer in an SEC filing dated Feb 3, 2022
- Jean Francois Formela · Last reported as a director in an SEC filing dated Aug 18, 2021
- Joel Sendek · Last reported as Chief Financial Officer in an SEC filing dated Jan 2, 2019
- Thomas R Parr JR · Last reported as Chief Scientific Officer in an SEC filing dated Jan 2, 2019
- Casper Breum · Last reported as a director in an SEC filing dated Jun 6, 2018
- David P Southwell · Last reported as a director in an SEC filing dated Jun 6, 2018
- Vikas Goyal · Last reported as a director in an SEC filing dated Nov 7, 2017
- Reza Halse · Last reported as a director in an SEC filing dated Nov 1, 2017
- Atlas Venture Fund IX, L.P. · Last reported as a 10% owner in an SEC filing dated Nov 1, 2017
- Atlas Venture Associates IX, LLC · Last reported as a 10% owner in an SEC filing dated Nov 1, 2017
- Atlas Venture Associates IX, L.P. · Last reported as a 10% owner in an SEC filing dated Nov 1, 2017
- Invest A/S Lundbeckfond · Last reported as a 10% owner in an SEC filing dated Nov 1, 2017
- Gv 2015, L.p. · Last reported as a 10% owner in an SEC filing dated Nov 1, 2017
- Gv 2015 Gp, L.l.c. · Last reported as a 10% owner in an SEC filing dated Nov 1, 2017
- Alphabet Inc. · Last reported as a 10% owner in an SEC filing dated Nov 1, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
SPRO Proposed Insider Sales (Form 144)
Latest: 2024-02-05
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2024-02-05 | SATYAVRAT SHUKLA | Officer, Director | 45,093 | $65.5K | 2024-02-05 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2023-08-29 | SATYAVRAT SHUKLA | Officer | 4,163 | $5.4K | 2023-08-29 | E*TRADE FINANCIAL CORPORATION | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-10-27
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Event | Link |
|---|---|---|
| 2026-10-27 | Director or officer change | EDGAR |
| 2026-08-28 | Material agreement · Other events | EDGAR |
| 2026-08-12 | Earnings results | EDGAR |
| 2026-07-14 | Material agreement · New debt obligation · Regulation FD disclosure · Other events | EDGAR |
| 2026-06-25 | Director or officer change · Bylaws or fiscal year change · Shareholder vote results | EDGAR |
| 2026-06-22 | Regulation FD disclosure · Other events | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-08-12 | 0001193125-26-346795 | EDGAR |
ETF Holders
6 ETFs hold SPRO
6 shown · $2.69M total exposure · 0.01% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $1.7M | — | 2026-09-30 |
| 2 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $717,837 | — | 2026-09-30 |
| 3 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.01% | $141,391 | $1.2B | 2026-11-06 |
| 4 | QQQS Invesco NASDAQ Future Gen 200 ETF | Invesco | 0.50% | $98,454 | — | 2026-11-05 |
| 5 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.00% | $31,540 | — | 2026-07-31 |
| 6 | DXUV Dimensional US Vector Equity ETF | Dimensional | 0.00% | $8,122 | — | 2026-11-05 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
4.00
TTM Diluted EPS
$0.27
TTM Revenue
$61.19M
TTM Net Income
$15.23M
TTM Op. Cash Flow
$7.24M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $258.00K | $-7.20M | $-0.13 | $15.86M |
| Q4 '25 | 2025-12-31 | $41.30M | $31.52M | $0.56 | $-8.35M |
| Q3 '25 | 2025-09-30 | $5.44M | $-7.38M | $-0.13 | $17.42M |
| Q2 '25 | 2025-06-30 | $14.19M | $-1.70M | $-0.03 | $-17.69M |
| Q1 '25 | 2025-03-31 | $5.87M | $-13.87M | $-0.25 | $-4.00M |
| Q4 '24 | 2024-12-31 | $15.04M | $-20.89M | $-0.38 | $-23.40M |
| Q3 '24 | 2024-09-30 | $13.47M | $-17.15M | $-0.32 | $12.76M |
| Q2 '24 | 2024-06-30 | $10.20M | $-17.86M | $-0.33 | $-18.74M |
| Q1 '24 | 2024-03-31 | $9.27M | $-12.67M | $-0.24 | $5.94M |
| Q4 '23 | 2023-12-31 | $73.52M | $51.19M | $0.97 | $-17.49M |
| Q3 '23 | 2023-09-30 | $25.47M | $-3.21M | $-0.06 | $15.91M |
| Q2 '23 | 2023-06-30 | $2.72M | $-11.91M | $-0.23 | $-18.56M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-13
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
4.00
P/B
1.17
P/S
1.01
EV/EBITDA
0.40
EV/Sales
0.09
ROE
28.8%
ROA
25.8%
Div Yield
0.00%
FCF Yield
11.73%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$61.73M
as of 2026-11-09
SPRO vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| ATRC AtriCure, Inc. | $3.0B | 275.1 | +13.9% | +47.1% | 33 |
| XNCR Xencor, Inc. | $2.7B | — | −28.6% | +164.4% | 38 |
| PCRX Pacira BioSciences, Inc. Common Stock | $1.5B | 104.2 | +5.7% | +49.1% | 66 |
| SIBN SI-BONE, Inc. Common Stock | $1.1B | — | +14.0% | +29.3% | 47 |
| KIDS OrthoPediatrics Corp. Common Stock | $829M | — | +16.1% | +93.6% | 24 |
| MYGN Myriad Genetics Inc | $564M | — | −3.2% | −6.1% | 36 |
| DTIL Precision BioSciences, Inc. Common Stock | $296M | — | +4802.1% | +141.1% | 40 |
| INGN Inogen Inc | $160M | — | +3.4% | −8.8% | 17 |
| SPRO Spero Therapeutics, Inc. Common Stock | $60M | 4.0 | +37.2% | −54.5% | 15 |
| Peer median | $961M | 189.7 | +9.8% | +48.1% | 37 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
840.53K
SI % of Float
2.00%
Days to Cover
1.51
Short Vol Ratio
40.6%
Free Float
42.11M
Float %
72.7%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-05-15